Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) CEO Jerome Jabbour tells Proactive the New Jersey-based company has closed a registered public offering of its stock, raising around $50 million gross. What's more, Jabbour commented on its peers' recent data in the Omega 3 area, how this affects the class in general, and more specifically Matinas' market share.
Full interview: Matinas BioPharma raises $50M to fund drug development, comments on peers' Omega 3 data
Quick facts: Matinas BioPharma
Price: 0.7694 USD
Market Cap: $153.01 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Matinas BioPharma named herein, including the promotion by the Company of Matinas BioPharma in any Content on the Site, the Company receives...FOR OUR FULL DISCLAIMER CLICK HERE